Subscribe To
XFOR / X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
XFOR News
By GlobeNewsWire
August 2, 2023
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule more_horizontal
By Seeking Alpha
May 6, 2023
X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors D more_horizontal
By GlobeNewsWire
April 26, 2023
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule more_horizontal
By Proactive Investors
April 12, 2023
X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study
X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 tri more_horizontal
By Seeking Alpha
April 12, 2023
X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match
Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market more_horizontal
By GlobeNewsWire
March 7, 2023
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecul more_horizontal
By Zacks Investment Research
January 31, 2023
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might d more_horizontal
By PennyStocks
December 21, 2022
Penny Stocks To Buy: 6 Insider Picks Before 2023
Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny more_horizontal